Rohto Pharmaceutical Co.,Ltd.
RPHCF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $686,249,487 | $708,857,750 | $523,245,886 | $414,643,496 |
| - Cash | $77,161,000 | $89,210,000 | $584,780 | $582,485 |
| + Debt | $50,223,000 | $10,494,000 | $102,458 | $21,383,000 |
| Enterprise Value | $659,311,487 | $630,141,750 | $522,763,563 | $435,444,012 |
| Revenue | $308,625,000 | $270,840,000 | $238,664,000 | $199,646,000 |
| % Growth | 14% | 13.5% | 19.5% | – |
| Gross Profit | $174,939,000 | $157,286,000 | $1,017,139 | $937,315 |
| % Margin | 56.7% | 58.1% | 0.4% | 0.5% |
| EBITDA | $56,423,000 | $50,401,000 | $42,338,000 | $35,811,000 |
| % Margin | 18.3% | 18.6% | 17.7% | 17.9% |
| Net Income | $31,006,000 | $30,936,000 | $26,377,000 | $21,127,000 |
| % Margin | 10% | 11.4% | 11.1% | 10.6% |
| EPS Diluted | 135.44 | 135.21 | 115.29 | 92.34 |
| % Growth | 0.2% | 17.3% | 24.9% | – |
| Operating Cash Flow | $36,917,000 | $34,245,000 | $232,765 | $223,859 |
| Capital Expenditures | -$10,561,000 | -$8,912,000 | -$74,578 | -$93,060 |
| Free Cash Flow | $26,356,000 | $25,333,000 | $158,187 | $130,799 |